Chen, Gege <br/><br/>
The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.  [electronic resource] 

 -  Oncology reports  Jul 2017 
 - 488-496 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1791-2431 
<br/><br/><label>Standard No.: </label>10.3892/or.2017.5675  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Blueberry Plants--chemistry<br/>Bortezomib--pharmacology<br/>Caspases--metabolism<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>DNA Damage--drug effects<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Histone Deacetylase Inhibitors--pharmacology<br/>Humans<br/>Hydroxamic Acids--pharmacology<br/>Indoles--pharmacology<br/>MAP Kinase Signaling System--drug effects<br/>Membrane Potential, Mitochondrial--drug effects<br/>Multiple Myeloma--drug therapy<br/>Neoplasm Recurrence, Local--drug therapy<br/>Panobinostat<br/>S Phase Cell Cycle Checkpoints--drug effects<br/>Stilbenes--pharmacology<br/>Vorinostat<br/>p38 Mitogen-Activated Protein Kinases--metabolism